Wellington Management Group’s Candel Therapeutics CADL Stock Holding History
Bought
Maintained
Sold
Other funds holding CADL
ACA
SVCM
Wellington Management Group's CADL Position: Q3 2026 in Review
Wellington Management Group increased its Candel Therapeutics (CADL) stake by 52% in Q3 2026, buying an estimated $1.19M and bringing the position to 313,005 shares worth $3.27M. The position accounts for ﹤0.01% of the portfolio, ranked #1513.
Wellington Management Group first reported a position in CADL in Q2 2025 and has held it in 4 quarters since. 141 funds tracked by Wall St. Rank hold CADL as of Q3 2026.
- Wellington Management Group held 313,005 shares of Candel Therapeutics worth $3.27M as of Q3 2026.
- Wellington Management Group bought 107,260 Candel Therapeutics shares in Q3 2026, an estimated $1.19M.
- Candel Therapeutics made up ﹤0.01% of Wellington Management Group's portfolio in Q3 2026, its #1513 holding.
- Wellington Management Group first reported a position in Candel Therapeutics in Q2 2025 and has held it in 4 quarters since.
- 141 funds tracked by Wall St. Rank held Candel Therapeutics as of Q3 2026.
Based on Wellington Management Group's 13F filing for Q3 2026, filed 16 Nov 2026.